Investor Type
×

Tell us once and we'll remember.

I'm an...

Don't worry, you can always change this selection using the icons at the top left of the site.
Institutional Investor Advisor Individual Investor

Commentary

Global Growth Strategy

First Quarter 2019

Key Takeaways
  • Stimulative economic policies and a bounce back of growth stocks from oversold positions drove strong performance for the market and the portfolio.
  • We took advantage of performance gains to take profits and reposition the portfolio across the three types of growth companies we target.
  • We believe the resolution of global trade issues and continued consumer strength across the U.S., Chinese and European markets should support growth stocks going forward.
Market Overview

Global equities staged a broad-based rally in the first quarter, rebounding from fourth-quarter lows on the likelihood of continued accommodation in Europe and China and a dovish turnabout by the U.S. Federal Reserve. The benchmark MSCI All Country World Index advanced 12.18%, led by a strong snapback in U.S. stocks as the Russell 3000 Index gained 14.04% while international developed market stocks in the MSCI EAFE Index rose 9.98% and the MSCI Emerging Market Index added 9.93%. Global growth stocks outperformed their value counterparts with the MSCI ACWI Growth Index up 14.48% for the quarter compared to a gain of 9.90% for the MSCI ACWI Value Index (Exhibit 1).

Exhibit 1: MSCI All Country World Growth vs Value Performance

Source: FactSet.

 

Global markets rose in the face of stubbornly weak economic data outside the U.S., particularly on the manufacturing side, and ongoing geopolitical headwinds. Manufacturing activity in both Europe and China has been contracting, with the ongoing trade disputes between the U.S. and China contributing to this malaise, impacting the outlook for global growth. Rising input costs on both the commodity front – Brent crude oil was up 24% in the quarter and copper 15% – and wages, have been hurting margins and raised concerns over continued negative earnings impacts.

 

"One area that has so far dodged the capex slowdown is IT, with spending on cloud related services especially robust."

 

Offsetting industrial weakness, services PMI is decidedly more positive with good job and wage growth in most regions. This has been positive for consumer spending, which, when combined with aggressive stimulus measures, have kept the non-manufacturing sectors of the markets in good shape. China has shifted from deleveraging to accommodative policies aimed at stimulating growth and consumption (rather than just increasing lending) and to protect against the negative effects of tariffs. Personal and VAT tax cuts, increases in lending facilities and other actions by China are sizable, representing 2.8% of GDP, and are focused on the consumer, state-owned enterprises and private companies.

The Chinese consumer has been particularly strong, both domestically and through tourism spending in places like Japan. Evidence of that strength has shown up in the performance of Alibaba, the Chinese e-commerce and media conglomerate that was one of the portfolio’s best performers during the first quarter. Japanese cosmetics maker Shiseido has benefited from the return of tourism spending after fears of decline with the new Chinese e-commerce law in January, as has luxury goods group LVMH. The consumer portions of the portfolio were some of the best performers to start the year, with the companies we own meaningfully outperforming similar stocks in the benchmark.

Moving west, stocks in Europe and the UK managed to hold up against a political backdrop that remains very much unsettled. As of this writing, the Brexit situation remains unresolved although we are optimistic about a neutral to positive outcome. A solution will likely be reached in April and we think a hard Brexit, the UK leaving the Common Union with trade governed by WTO rules, is unlikely. The UK currently has three options: accept Prime Minister Theresa May’s Brexit proposal, hold a second national referendum on Brexit – basically a re-vote by a British population with a much better understanding of what leaving the EU entails than three years ago – or revoke Article 50 altogether and remain in the EU as if nothing ever happened. The portfolio has limited exposure to domestic UK businesses and we are optimistic that this will not remain a distraction much longer.

While the ECB has not made drastic moves like the Chinese government, its decision during the first quarter to keep interest rates lower for longer has sparked a rally in growth stocks. In a moderating economy like we are seeing across most of our target markets, growth investors can benefit from rising revenue and earnings and a lower cost of capital. Lower rates are also positive for M&A activity.

U.S. equities are rallying again against a decidedly mixed economic backdrop. The Federal Reserve paused its rate tightening program during the quarter, satisfied that inflation is under control and that the current moderate pace of U.S. GDP growth can be maintained. Continued solid employment numbers and strengthening wage growth suggest the U.S. consumer is in good shape. But weaker manufacturing data and a yield curve inversion in March, coupled with the lack of resolution to trade negotiations between the U.S. and China, suggest business activity could slow going forward.

One area that has so far dodged the capex slowdown is IT, with spending on cloud related services especially robust. Here the portfolio has benefited from exposure to hyperscale cloud providers Amazon.com and Microsoft. We added to our cloud exposure in the first quarter with the purchase of Equinix, a data center provider that houses server and storage capacity and is directly tied to the shift to hybrid-cloud IT infrastructures. The unique benefits of Equinix’s dense network of interconnections should enable the company to grow revenues at an 8-12% long-term rate.

Portfolio Positioning

Global growth stocks enjoyed some of their strongest gains in several years in the first quarter and consistent with our valuation and risk-focused approach, we took some profits. In the health care sector, we closed a position in Mettler-Toledo as the U.S.-based supplier of precision instruments, solutions and services to the laboratory, industrial and food retailing industries hit our target price; as well as Rentokil, a British-based provider of extermination and hygiene services that has seen its stock move steadily higher thanks to its ability to accretively consolidate a fragmented industry.

The proceeds of these sales were directed into several new names across our emerging, secular and structural growth buckets. This diversified approach allows us to access growth in all its forms while helping to control risk. In the emerging growth bucket of higher risk companies with above-average top line growth, we tapped into an attractive IPO market with the purchase of Tencent Music (TME). TME is the leader in Chinese online music with 800 million monthly average users, eight times the nearest competitor. We expect the company to sustain strong top line growth for years to come as its investment in exclusive content drives the paying user ratio above current 4% levels.

The purchase of Novartis, a Swiss-based global pharmaceutical firm, adds to our group of secular growers that typically offer stability to the portfolio with limited volatility and good downside protection. Following the spinout of its eyecare business Alcon, we believe Novartis will be a cleaner story. We see potential upside in many of their pharmaceutical franchises and believe their pipeline of products has sufficiently differentiated treatments. A new CEO is transitioning the company away from a conglomerate structure to focus on prescription medicines, increasing the pace of innovation and redeploying capital toward higher science advanced technology platforms.

We also re-established a position in Taiwan Semiconductor (TSM), a name we have owned in the past. TSM is a classic structural growth company, where its future growth path should be much different than the recent past, in this case due to what we see as a cyclical upswing in the semiconductor cycle. The stock is back to trading at trough multiples relative to the S&P 500 Index and we think we are past the cyclical weakness in smartphones and cryptocurrency as well as inventory restocking, and that new product cycles around data centers and 5G should re-accelerate growth. Additionally, TSM has seen a structural shift and is now leading in technological execution, allowing it better pricing, and potentially many more clients. The purchase of Spin Master, a Canadian toy maker and entertainment company, is another structural play that has a very interesting pipeline of new products. The Toys R Us bankruptcy caused the toy market, especially in the U.S., to become highly promotional, providing a one-time opportunity to get into a well-positioned company.

Outlook

While the U.S. is beginning to feel the effects of slowing earnings growth, EU earnings remain depressed and well off their past peak. We see several catalysts that could jumpstart earnings over the course of 2019. We have seen currency headwinds rolling through many of the European companies, which has depressed attractive constant currency growth. We believe the FX effects should start to roll off in the second quarter and by the second half of the year, this should improve investor sentiment around European equities. We have also been seeing higher producer prices which should lead to pricing power taking hold across industries. This in turn should lead to revenue and operating results as price increases go through. And finally, the EU is more exposed to emerging markets than the U.S. and as emerging markets demand becomes less depressed, that should flow through to earnings.

With respect to China, we see recent consumer strength continuing. A resolution in trade negotiations would also help improve sentiment and provide companies all over the world a more predictable playbook from which to manage their businesses. We also expect China’s efforts to expand the money supply begin to take effect later in the year, which should provide support to the struggling manufacturing side of their economy.

The current U.S. economic expansion is showing signs of age. Rather than try to time shifts in the economy, our focus remains on portfolio companies and sourcing new growth ideas. A valuation approach to portfolio construction, characterized by the three buckets of growth companies detailed above, helps promote consistent long-term results. This perspective allows us to be more active buyers during periods of price dislocation.

Portfolio Highlights

The ClearBridge Global Growth Strategy outperformed the benchmark MSCI All Country World Index for the first quarter. The Strategy delivered gains across the 10 sectors in which it was invested (out of 11 total), with the primary contributors coming from the IT, financials and consumer discretionary sectors.

On a relative basis, overall stock selection and sector allocation contributed to performance. In particular, stock selection in the financials, health care and consumer discretionary sectors and an overweight to IT drove relative results. Conversely, stock selection in the communication services sector and an underweight to the energy sector detracted from relative performance.

On a regional basis, stock selection in Europe Ex UK and emerging markets had the most significant positive impacts.

On an individual stock basis, the largest contributors to absolute returns in the quarter included Worldpay, Alibaba, LVMH, Shopify and AIA Group. The greatest detractors from absolute returns included positions in Hansa Biopharma, Tesla, Spin Master, MonotaRO and Pfizer.

During the quarter, in addition to the names mentioned above we added several other new positions, the largest being Equinix in the real estate sector, ICON in the health care sector as well as Aspen Technology, Guidewire Software and ServiceNow in the IT sector. The Strategy also closed several positions, the largest being Johnson & Johnson in the health care sector, Rentokil in the industrials sector and, Keyence in the IT sector.

Elisa Mazen

Head of Global Growth, Portfolio Manager
34 Years experience
11 Years at ClearBridge

Thor Olsson

Portfolio Manager
22 Years experience
19 Years at ClearBridge

Michael Testorf, CFA

Portfolio Manager
32 Years experience
4 Years at ClearBridge

Pawel Wroblewski, CFA

Portfolio Manager
23 Years experience
11 Years at ClearBridge

Related Perspectives

  • Past performance is no guarantee of future results.

  • All opinions and data included in this commentary are as of the publication date and are subject to change. The opinions and views expressed herein are of the author and may differ from other portfolio managers or the firm as a whole, and are not intended to be a forecast of future events, a guarantee of future results or investment advice. This information should not be used as the sole basis to make any investment decision. The statistics have been obtained from sources believed to be reliable, but the accuracy and completeness of this information cannot be guaranteed. Neither ClearBridge Investments, LLC  nor its information providers are responsible for any damages or losses arising from any use of this information. 

  • Performance source: Internal. Benchmark source: Morgan Stanley Capital International. Neither ClearBridge Investments, LLC nor its information providers are responsible for any damages or losses arising from any use of this information. Performance is preliminary and subject to change.

    Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI’s express written consent. Further distribution is prohibited.